mol42
23 May 2017
Hardman 240517 [link]
TheDrewster
23 May 2017
Re: Up up and away ? People beginning to grasp the significance of the China IP, the Moderna deal, or the two new US Bio deals ... there are significant (potential) positives, even if the terms of the commercials are tied up in confidentiality handcuffs.
Chancellor Jon
23 May 2017
Up up and away ? Any thoughts folks on todays big jump ?Thanks in advance.CJ.
mol42
17 May 2017
Turner Pope recently initiated coverage[link] are they? well we haven't made it here yet[link]
mol42
10 May 2017
just announced [link]
Proverbs 26 vs 5
10 May 2017
Good news but not enough for me to invest StockMarketWire.com - Avacta Group has announced that the principal patent protecting the Affimer technology had been accepted for grant in China. Avacta said that on issuance, this patent would extend coverage of Avacta's intellectual property into another potentially large market for the company.It said that considering the therapeutic applications of Affimers alone, China now accounted for more than one fifth of the global therapeutic antibody market. It said counterparts to this patent had already been granted in the US, Europe and Japan.Group chief executive Dr Alastair Smith said:"The grant of a robust patent to cover the core Affimer intellectual property in China adds further strength to our global intellectual property position. "We continue to develop the core technology and I look forward to updating the market regarding further expansion of our Affimer intellectual property estate in due course." At 9:53am: [LON:AVCT] Avacta Group PLC share price was +4.5p at 90pStory provided by StockMarketWire.com
mol42
05 May 2017
RNS further to rns - hardman note[link] i don't expect a vast improvement to 310717 in financials - i do expect a substantial improvement to 310718 - more than hardman forecast! next 8 months to this calendar year end will help me decidebw allmol
mol42
04 May 2017
Re: Moderna [link] news to come regarding further payments to us - they have, as previously noted,a substantial cash balance and an ongoing contact with uswe will see - perhaps sooner than later!i can wait mol
mol42
04 May 2017
Re: Moderna Extract Hardman noteThe distinguishing attributes of Affimers have attracted the interest of pharmaceutical and biotechnology majors.In 2015, Avacta announced a number of deals, but the most significant was a research partnership with Moderna Therapeutics to provide a range of Affimers against a number of selected targets for messenger RNA therapeutics. Moderna initially paid $0.5m for exclusive access to Affimers against certain targets which was an important endorsement of Avacta’s technology. update - news from moderna[link]
mol42
29 Apr 2017
Re: 260417 presentation top three diagnostic companies named by A Smiththat should put an end to speculation on other BB's......... perhaps mol
mol42
29 Apr 2017
Re: 260417 presentation first question in front row at c25m injees from back looked like Paulmol
mol42
29 Apr 2017
Re: 260417 presentation oops just correcting thread heading - published 27thjust me - like to get dates right - lolmol
mol42
29 Apr 2017
270417 presentation [link]
mol42
29 Apr 2017
Riccardo Lowi - Capital Network yesterday[link]
mol42
26 Apr 2017
Re: Tonight's presentation slides of particular noteFY17 forecast c.£1.2m revenues from paid-for evaluations and customised Affimer generation compared to half year 17Half year revenues increased 20% to £1.3m (£1.0m FY16) comprising of £0.5m (£0.3m FY16) from Avacta Life Sciences and £0.8m (£0.7m FY16) from Avacta Animal Health.paid for evaluations should not be netted off against expenditure but even if so still contributing to overall performance - anyway 700k in second half forecast at least - prior to any further upfront paymentsmol
